Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Preliminary Results of a Phase 1, Dose‑Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed / Refractory Lymphoid Malignancies

Tuesday, December 10, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses preliminary results from a Phase 1 dose-escalation study of PRT2527, a selective CDK9 inhibitor. The study evaluates PRT2527 both as a monotherapy and in combination with Zanubrutinib in patients with relapsed or refractory lymphoid malignancies. Early findings suggest potential benefits in treatment efficacy, warranting further investigation.
Price reaction · baseline $1.03 (2024-12-09 close) · hit pre-market · 2 other PRLD headline(s) in the window, move may be shared
day 0 close
-5.8%
day 1
-8.7%
day 3 · peak
-22.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study shows promising preliminary results for PRT2527.
  • Combination therapy with Zanubrutinib may enhance treatment efficacy.
  • The drug targets CDK9, which is crucial for cancer cell proliferation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Katharine L. Lewis, Wojciech Jurczak, Gareth P. Gregory,Constantine S. Tam, Won Seog Kim,Eliza A. Hawkes, Franck Morschhauser, Sarit E. Assouline, Geoffrey Shouse, Petra Langerbeins, Monica Tani, Young Rok Do, Bruce D. Cheson, Catherine S. Diefenbach, Craig A. Portell, Jennifer Xavier, Muhtarjan Osman, Siminder K. Atwal, Wan‑Jen Hong, Clémentine Sarkozy

Frequently Asked Questions

What is PRT2527?

PRT2527 is a potent and highly selective CDK9 inhibitor being studied for cancer treatment.

What type of study was conducted for PRT2527?

A Phase 1 dose-escalation study was conducted to evaluate PRT2527.

How is PRT2527 administered?

PRT2527 is evaluated both as a monotherapy and in combination with Zanubrutinib.

What cancers are targeted by PRT2527?

PRT2527 targets relapsed or refractory lymphoid malignancies.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT2527 CDK9 inhibitor Zanubrutinib lymphoid malignancies Phase 1 study
Last updated: Dec 10, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →